四环生物股票讨论区

The 11% compound share price fall over three years is justified by fundamental deterioration. Uncertainty looms over future profitability without more cash. Last year's performance indicates unresolved challenges, worse than the annualised loss of 0.3% over the last half decade. Investors should heed 2 warning signs.

The high P/S ratio at Jiangsu Sihuan Bioengineering, despite falling revenue and unsatisfactory medium-term growth, is a concern. Unless there's a significant medium-term turnaround, the stock might be overvalued, risking investor disappointment.